Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Dalteparin vs placebo Number of other sickle‐related events ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Hospitalisation (number and duration) ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Adverse events associated with the use of anticoagulants (e.g. bleeding) ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Tinzaparin vs placebo Number of serious complications of SCD ‐ not measured · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Tinzaparin vs placebo Number of other sickle‐related events ‐ not measured · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Tinzaparin vs placebo Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Tinzaparin vs placebo Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Severe adverse events or withdrawals (due to adverse events) ‐ not reported · People with hip or knee osteoarthritis High‐intensity versus low‐intensity physical activity or exercise in people with hip or knee osteoarthritis (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse event · participants with CHD after PCI Tong‐xin‐luo capsule for patients with coronary heart disease after percutaneous coronary intervention (2015) · Cochrane | no estimate extracted | NR | No studies |
Bovine lung lavage surfactant extract vs modified bovine minced lung surfactant extract Neurodevelopmental outcome at approximately two years’ corrected age · Preterm infants for treatment of RDS Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome… (2015) · Cochrane | no estimate extracted | NR | No studies |
Bovine lung lavage surfactant extract vs porcine minced lung surfactant extract Death or oxygen requirement at 36 weeks' postmenstrual age · Preterm infants for treatment of RDS Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome… (2015) · Cochrane | no estimate extracted | NR | No studies |
Bovine lung lavage surfactant extract vs porcine minced lung surfactant extract Pneumothorax · Preterm infants for treatment of RDS Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome… (2015) · Cochrane | no estimate extracted | NR | No studies |
Bovine lung lavage surfactant extract vs porcine minced lung surfactant extract Pulmonary hemorrhage · Preterm infants for treatment of RDS Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome… (2015) · Cochrane | no estimate extracted | NR | No studies |
Bovine lung lavage surfactant extract vs porcine minced lung surfactant extract Neurodevelopmental outcome at approximately two years’ corrected age · Preterm infants for treatment of RDS Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome… (2015) · Cochrane | no estimate extracted | NR | No studies |
Modified bovine minced lung surfactant extract vs porcine minced lung surfactant extract Neurodevelopmental outcome at approximately two years’ corrected age · Preterm infants for treatment of RDS Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome… (2015) · Cochrane | no estimate extracted | NR | No studies |
Modified bovine minced lung surfactant extract vs porcine lung lavage surfactant Oxygen requirement at 36 weeks' postmenstrual age · Preterm infants for treatment of RDS Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome… (2015) · Cochrane | no estimate extracted | NR | No studies |
Modified bovine minced lung surfactant extract vs porcine lung lavage surfactant Death or oxygen requirement at 36 weeks' postmenstrual age · Preterm infants for treatment of RDS Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome… (2015) · Cochrane | no estimate extracted | NR | No studies |
Modified bovine minced lung surfactant extract vs porcine lung lavage surfactant Pulmonary hemorrhage · Preterm infants for treatment of RDS Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome… (2015) · Cochrane | no estimate extracted | NR | No studies |
Modified bovine minced lung surfactant extract vs porcine lung lavage surfactant Severe intraventricular hemorrhage in infants who received neuroimaging · Preterm infants for treatment of RDS Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome… (2015) · Cochrane | no estimate extracted | NR | No studies |
Modified bovine minced lung surfactant extract vs porcine lung lavage surfactant Neurodevelopmental outcome at approximately two years corrected age · Preterm infants for treatment of RDS Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome… (2015) · Cochrane | no estimate extracted | NR | No studies |
Bovine lung lavage surfactant extract vs modified bovine minced lung surfactant extract Neurodevelopmental outcome at approximately two years’ corrected age · Preterm infants for prevention of RDS Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · participants with low back pain Pilates for low back pain (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · patients with low back pain Pilates for low back pain (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · patients undergoing orthognathic surgery Antibiotic prophylaxis for preventing infectious complications in orthognathic surgery (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Systemic infection · patients undergoing orthognathic surgery Antibiotic prophylaxis for preventing infectious complications in orthognathic surgery (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · patients undergoing orthognathic surgery Antibiotic prophylaxis for preventing infectious complications in orthognathic surgery (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Duration of hospital stay · patients undergoing orthognathic surgery Antibiotic prophylaxis for preventing infectious complications in orthognathic surgery (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · patients undergoing orthognathic surgery Antibiotic prophylaxis for preventing infectious complications in orthognathic surgery (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Systemic infection · patients undergoing orthognathic surgery Antibiotic prophylaxis for preventing infectious complications in orthognathic surgery (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Duration of hospital stay · patients undergoing orthognathic surgery Antibiotic prophylaxis for preventing infectious complications in orthognathic surgery (2015) · Cochrane | no estimate extracted | NR | No studies |
Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg Participant‐reported improvement of hirsutism ‐ not measured · patients with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg Change in health‐related quality of life (HRQOL) ‐ not measured · patients with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg Change in BMI ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Spironolactone 100 mg vs placebo Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Spironolactone 100 mg vs placebo Change in BMI ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Spironolactone 100 mg vs placebo Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Finasteride 5 mg to 7.5 mg vs placebo Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Finasteride 5 mg to 7.5 mg vs placebo Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Metformin 500 mg to 2550 mg per day vs placebo Participant‐reported improvement of hirsutism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Metformin 500 mg to 2550 mg per day vs placebo Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Metformin 500 mg to 2550 mg per day vs placebo Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Finasteride 5 mg vs spironolactone 100 mg Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Finasteride 5 mg vs spironolactone 100 mg Change in BMI ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Finasteride 5 mg vs spironolactone 100 mg Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Flutamide 250 mg once to twice daily vs metformin 1275 mg to 1700 mg per day Participant‐reported improvement of hirsutism ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |
Flutamide 250 mg once to twice daily vs metformin 1275 mg to 1700 mg per day Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism Interventions for hirsutism (excluding laser and photoepilation therapy alone) (2015) · Cochrane | no estimate extracted | NR | No studies |